120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study
Titel:
120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study
Auteur:
Yang, J.C-H. Luft, A. De La Mora Jiménez, E. Lee, J.S. Koralewski, P. Karadurmus, N. Sugawara, S. Livi, L. Basappa, N.S. Quantin, X. Dudnik, J. Moran Ortiz, D. Mekhail, T. Okpara, C.E. Zimmer, Z. Samkari, A. Bhagwati, N. Csőszi, T.